Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Incyte Corporation (NASDAQ:INCY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants William Meury - CEO, President & Director Steven Stein ...
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
Incyte's share price continues to soar despite Trump's repeated threats to cut drug prices. One of the key reasons behind the continued upward momentum was Incyte's strong financial results for Q2 ...
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
During a year when healthcare stocks, especially biotechnology, have lagged so deeply behind the overall market, it's particularly noteworthy that Incyte Corporation NASDAQ: INCY has managed to sta...
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Incyte: New CEO Brings A New Possible Outcome
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with...
Incyte Says FDA Extended Review Period for Opzelura
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloprolifer...
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboratio...
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025.
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Off...
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Related Companies